Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy

[1] Kuderer NM(2007)Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review J Clin Oncol 25 3158-3167

[2] Dale DC(2010)Risk of mortality in patients with cancer who experience febrile neutropenia Cancer 116 5555-5563

[3] Crawford J(2011)Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy Cancer 117 1917-1927

[4] Lyman GH(2006)2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 3187-3205

[5] Lyman GH(2011)2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours Eur J Cancer 47 8-32

[6] Michels SL(2005)Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort J Clin Oncol 23 8620-8628

[7] Reynolds MW(2007)Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3–4 week chemotherapy regimens in community oncology practices J Manag Care Pharm 13 337-348

[8] Barron R(2011)Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study Curr Med Res Opin 27 79-86

[9] Tomic KS(2006)Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40 402-407

[10] Yu J(2012)Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy Am J Clin Oncol 35 267-274

[1] Kuderer NM(2007)Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review J Clin Oncol 25 3158-3167

[2] Dale DC(2010)Risk of mortality in patients with cancer who experience febrile neutropenia Cancer 116 5555-5563

[3] Crawford J(2011)Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy Cancer 117 1917-1927

[4] Lyman GH(2006)2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 3187-3205

[5] Lyman GH(2011)2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours Eur J Cancer 47 8-32

[6] Michels SL(2005)Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort J Clin Oncol 23 8620-8628

[7] Reynolds MW(2007)Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3–4 week chemotherapy regimens in community oncology practices J Manag Care Pharm 13 337-348

[8] Barron R(2011)Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study Curr Med Res Opin 27 79-86

[9] Tomic KS(2006)Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40 402-407

[10] Yu J(2012)Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy Am J Clin Oncol 35 267-274